(NTLA) Intellia Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45826J1051

Genome Editing, Gene Therapy, Cell Therapies

NTLA EPS (Earnings per Share)

EPS (Earnings per Share) of NTLA over the last years for every Quarter: "2020-03": -0.63, "2020-06": -0.61, "2020-09": -0.47, "2020-12": -0.69, "2021-03": -0.69, "2021-06": -1.01, "2021-09": -0.97, "2021-12": -1.09, "2022-03": -1.96, "2022-06": -1.32, "2022-09": -1.49, "2022-12": -1.44, "2023-03": -1.05, "2023-06": -1.4, "2023-09": -1.38, "2023-12": -1.46, "2024-03": -1.12, "2024-06": -1.52, "2024-09": -1.34, "2024-12": -1.27, "2025-03": -1.1,

NTLA Revenue

Revenue of NTLA over the last years for every Quarter: 2020-03: 12.916, 2020-06: 16.263, 2020-09: 22.22, 2020-12: 6.595, 2021-03: 6.445, 2021-06: 6.55, 2021-09: 7.204, 2021-12: 12.854, 2022-03: 11.252, 2022-06: 14.03, 2022-09: 13.266, 2022-12: 13.573, 2023-03: 12.606, 2023-06: 13.594, 2023-09: 11.992, 2023-12: -1.917, 2024-03: 28.935, 2024-06: 6.957, 2024-09: 9.111, 2024-12: 12.874, 2025-03: 16.627,

Description: NTLA Intellia Therapeutics

Intellia Therapeutics, Inc. is a pioneering gene editing company that is revolutionizing the treatment of various diseases through its innovative genome editing technologies. With a strong focus on developing curative treatments, the companys in vivo programs are making significant progress, including NTLA-2001, which is being evaluated in a Phase 1 clinical trial for the treatment of transthyretin amyloidosis, a debilitating condition with limited treatment options.

The companys pipeline also includes NTLA-2002, a promising treatment for hereditary angioedema, which is currently in a Phase 1/2 study. Additionally, Intellia is actively researching proprietary programs aimed at developing engineered cell therapies to combat various cancers and autoimmune diseases, demonstrating its commitment to addressing a broad range of medical needs.

Intellia has established strategic partnerships with leading companies, including AvenCell Therapeutics, Kyverna Therapeutics, ONK Therapeutics, and ReCode Therapeutics, to accelerate the development of novel therapies. These collaborations are focused on creating allogeneic universal CAR-T cell therapies, CD19 CAR-T cell therapies for B cell-mediated autoimmune diseases, engineered NK cell therapies for cancer, and genomic medicines for cystic fibrosis, further expanding Intellias reach and potential impact.

Analyzing the technical data, NTLAs last price is $9.60, with a 20-day SMA of $8.46 and a 50-day SMA of $8.18, indicating a positive short-term trend. However, the 200-day SMA of $12.47 suggests that the stock has been trending downward over the longer term. The ATR of 0.75 represents a 7.77% average daily price range, indicating moderate volatility. Given the current price and the 52-week high and low of $27.36 and $6.28, respectively, it is likely that the stock will continue to experience fluctuations.

From a fundamental perspective, Intellias market capitalization is approximately $994.40 million, with a negative P/E ratio and a Return on Equity of -58.67%. This suggests that the company is still in a growth phase and has not yet achieved profitability. However, the companys innovative pipeline and strategic partnerships have the potential to drive future growth.

Forecasting NTLAs future performance, we can expect the stock to be influenced by the progress of its clinical trials, particularly NTLA-2001 and NTLA-2002. Positive results from these trials could lead to increased investor confidence and a subsequent rise in the stock price. Additionally, the companys collaborations and partnerships are likely to play a crucial role in shaping its future growth trajectory. Based on the current technical and fundamental data, a potential price target for NTLA could be in the range of $12-15, representing a 25-50% increase from the current price, assuming successful trial results and continued progress in its pipeline.

Additional Sources for NTLA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

NTLA Stock Overview

Market Cap in USD 1,112m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2016-05-06

NTLA Stock Ratings

Growth Rating -64.1
Fundamental -
Dividend Rating 0.0
Rel. Strength -49.3
Analysts 4.34 of 5
Fair Price Momentum 8.48 USD
Fair Price DCF -

NTLA Dividends

Currently no dividends paid

NTLA Growth Ratios

Growth Correlation 3m 69.8%
Growth Correlation 12m -93.3%
Growth Correlation 5y -66.5%
CAGR 5y -13.73%
CAGR/Max DD 5y -0.14
Sharpe Ratio 12m -0.44
Alpha -84.14
Beta 2.520
Volatility 90.56%
Current Volume 2811.3k
Average Volume 20d 4735k
What is the price of NTLA shares?
As of July 06, 2025, the stock is trading at USD 10.74 with a total of 2,811,328 shares traded.
Over the past week, the price has changed by +12.34%, over one month by +40.03%, over three months by +61.99% and over the past year by -52.81%.
Is Intellia Therapeutics a good stock to buy?
No, based on ValueRay´s Analyses, Intellia Therapeutics (NASDAQ:NTLA) is currently (July 2025) a stock to sell. It has a ValueRay Growth Rating of -64.06 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NTLA is around 8.48 USD . This means that NTLA is currently overvalued and has a potential downside of -21.04%.
Is NTLA a buy, sell or hold?
Intellia Therapeutics has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy NTLA.
  • Strong Buy: 18
  • Buy: 4
  • Hold: 6
  • Sell: 1
  • Strong Sell: 0
What are the forecasts for NTLA share price target?
According to our own proprietary Forecast Model, NTLA Intellia Therapeutics will be worth about 10.2 in July 2026. The stock is currently trading at 10.74. This means that the stock has a potential downside of -5.21%.
Issuer Target Up/Down from current
Wallstreet Target Price 37.3 247.3%
Analysts Target Price 37.3 247.3%
ValueRay Target Price 10.2 -5.2%